Physician profile
Jonathan H Schwartz
NPI 1053393462
$92,892.95
in general payments reported to CMS, 2019-2025
20 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $906 · 2020: $477 · 2021: $392 · 2022: $1,463 · 2023: $1,312 · 2024: $87K · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $86K · Food and Beverage: $3,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $85,875.00 |
| Food and Beverage | $3,779.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $88,011.68 | 2019-2025 | Neurostar Tms Therapy System |
| Abbvie INC. | $831.85 | 2022-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $757.97 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $554.17 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $526.94 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $503.59 | 2019-2022 | |
| Lundbeck LLC | $405.04 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $251.64 | 2019-2025 | Spravato, Invega Sustenna |
| Corium, LLC | $161.64 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $156.50 | 2022-2023 | Qelbree |
| Alkermes, INC. | $149.20 | 2022-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $126.31 | 2021-2025 | Fanapt, Hetlioz |
| Indivior INC. | $126.25 | 2019-2020 | |
| Shire North American Group INC | $92.33 | 2019 | |
| Ironshore Pharmaceuticals INC. | $86.24 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $45.83 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $43.45 | 2019-2024 | Uzedy, Austedo Xr |
| Allergan, INC. | $26.61 | 2019-2020 | |
| Avion Pharmaceuticals | $21.99 | 2023 | Methylphenidate Hydrochloride |
| Takeda Pharmaceuticals U.S.A., INC. | $13.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.